3 Reasons to Buy Roku, and 1 Reason to Avoid It

The streaming media company's business is firing on all cylinders -- but does that justify its frothy stock valuations? Read More...

Motley Fool

Where Will ARK Genomic Revolution ETF Be in 5 Years?

Technology improvements and cost reductions in genetic testing and therapies are making it possible to diagnose, treat, and even cure devastating diseases. ARK management believes these advancements are ushering in a “Genomic Age” that could create trillions of dollars in equity market capitalization by 2024. To take advantage of these trends, the ARK Genomic Revolution ETF (NYSEMKT: ARKG) invests in companies proving to be “leaders, enablers, and beneficiaries” of CRISPR (a gene-editing technique), targeted therapeutics, bioinformatics, molecular diagnostics, stem cells, agricultural biology, and healthcare innovation.

Read More